Insilico Medicine to present first-in-human data for AI-designed pan-TEAD inhibitor ISM6331 at ESMO 2026
Insilico Medicine strengthens its middle east presence with potential blood cancer treatment, generated by AI, first of its kind in the UAE
Across four global innovation hubs: Insilico Medicine executive team to speak at premier healthcare and AI Summits
Across four global innovation hubs: Insilico Medicine executive team to speak at premier healthcare and AI Summits
Insilico Medicine doses first patient in GENESIS-IPF-3, the world’s first phase III trial of a generative AI-driven innovative drug
Insilico Medicine included in the HKEX Tech 100 Index, drawing attention to opportunities in AI value chain
Weekly Event Preview | Insilico Medicine leadership to speak at LEAP 2026 and top financial summits
Insilico Medicine convenes O3DC, an open consortium for benchmark quality in AI-driven drug discovery
Insilico Medicine earns second consecutive Prix Galien USA “Best Start-Up” Nomination
Insilico Medicine included in MSCI Global Small Cap Indexes, gaining capital market endorsement in core strengths
Insilico Medicine introduces biological age into virtual cell research: launches virtual aging cell webpage and previews multi-agent driven VAC generation platform - EurekAlert!
Insilico Medicine nominates ISM0900, a potent, AI-driven, oral Lp(a) inhibitor, as PCC for management of cardiovascular risks - EurekAlert!
Science Signaling | Insilico Medicine contributes to research using AI to reveal NDRG1-associated DNA repair mechanisms and potential synthetic lethal effects in colorectal cancer - EurekAlert!
AI-empowered pipeline-in-a-drug option: Insilico Medicine nominates ISM9077, potential first-in-class target Y inhibitor, as preclinical candidate (PCC) for ocular diseases, inflammatory disorders and aging - EurekAlert!
Insilico Medicine receives NMPA IND clearance for innovative oral candidate ISM8969/HT-001, the brain-penetrant NLRP3 inhibitor co-developed with Hygtia Therapeutics - EurekAlert!
Weely Conference: Insilico Medicine at Ai4 2026: Dr. Alex Zhavoronkov to deliver two keynote sessions on AI drug discovery and anti-aging - EurekAlert!
Insilico Medicine announces oral presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in mesothelioma and advanced solid tumors - EurekAlert!
Weekly Events | Insilico Medicine executives at CPIC: navigating the dual breakthrough of tech innovation and clinical validation in AI drug discovery - EurekAlert!
Insilico Medicine and Bora Pharmaceuticals announce strategic alliance for AI-driven drug discovery and development - EurekAlert!
Insilico Medicine and Eli Lilly to anchor 13th Aging Research & Drug Discovery (ARDD) meeting at the David Rubenstein Treehouse at Harvard University - EurekAlert!
